BIOMAT Database Logo BIOMAT Database Logo

The Synthesis and Biological Evaluation of 2-(1H-Indol-3-yl)quinazolin-4(3H)-One Derivatives. 2023

Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Department of Chemistry, Perm State University, Bukireva St. 15, 614990 Perm, Russia.

The treatment of many bacterial diseases remains a significant problem due to the increasing antibiotic resistance of their infectious agents. Among others, this is related to Staphylococcus aureus, especially methicillin-resistant S. aureus (MRSA) and Mycobacterium tuberculosis. In the present article, we report on antibacterial compounds with activity against both S. aureus and MRSA. A straightforward approach to 2-(1H-indol-3-yl)quinazolin-4(3H)-one and their analogues was developed. Their structural and functional relationships were also considered. The antimicrobial activity of the synthesized compounds against Mycobacterium tuberculosis H37Rv, S. aureus ATCC 25923, MRSA ATCC 43300, Candida albicans ATCC 10231, and their role in the inhibition of the biofilm formation of S. aureus were reported. 2-(5-Iodo-1H-indol-3-yl)quinazolin-4(3H)-one (3k) showed a low minimum inhibitory concentration (MIC) of 0.98 μg/mL against MRSA. The synthesized compounds were assessed via molecular docking for their ability to bind long RSH (RelA/SpoT homolog) proteins using mycobacterial and streptococcal (p)ppGpp synthetase structures as models. The cytotoxic activity of some synthesized compounds was studied. Compounds 3c, f, g, k, r, and 3z displayed significant antiproliferative activities against all the cancer cell lines tested. Indolylquinazolinones 3b, 3e, and 3g showed a preferential suppression of the growth of rapidly dividing A549 cells compared to slower growing fibroblasts of non-tumor etiology.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Synthesis and biological evaluation of certain 3-substituted benzylideneamino-2-(4-nitrophenyl)quinazolin-4(3H)-one derivatives.
April 2015, Journal of enzyme inhibition and medicinal chemistry,
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Synthesis and antiproliferative activity of novel 3-(indazol-3-yl)-quinazolin-4(3H)-one and 3-(indazol-3-yl)-benzotriazin-4(3H)-one derivatives.
September 1999, Archiv der Pharmazie,
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Synthesis and pharmacological activities of novel 3-(isoxazol-3-yl)-quinazolin-4(3H)-one derivatives.
February 1999, Archiv der Pharmazie,
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Novel N-Substituted 2-(2-(Adamantan-1-yl)-1H-Indol-3-yl)-2-Oxoacetamide Derivatives: Synthesis and Biological Evaluation.
May 2016, Molecules (Basel, Switzerland),
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Synthesis and biological evaluation of 3-(1H-indol-3-yl)pyrazole-5-carboxylic acid derivatives.
March 2011, Archives of pharmacal research,
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Synthesis and cytotoxic evaluation of some new 3-(2-(2-phenylthiazol-4-yl) ethyl)-quinazolin-4(3H) one derivatives with potential anticancer effects.
August 2017, Research in pharmaceutical sciences,
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
Synthesis and study the antimicrobial activity of novel 2-(1H-indol-3-yl)- N-(3, 4-diphenylthiazol-2(3H)-ylidene) ethanamine derivatives.
March 2013, Medicinal chemistry (Shariqah (United Arab Emirates)),
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
3-(4-Bromo-phen-yl)quinazolin-4(3H)-one.
November 2011, Acta crystallographica. Section E, Structure reports online,
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
3-(4-Chloro-phen-yl)quinazolin-4(3H)-one.
September 2011, Acta crystallographica. Section E, Structure reports online,
Elena Y Mendogralo, and Larisa Y Nesterova, and Ekaterina R Nasibullina, and Roman O Shcherbakov, and Alexander G Tkachenko, and Roman Y Sidorov, and Maxim A Sukonnikov, and Dmitry A Skvortsov, and Maxim G Uchuskin
3-[(2-Chloro-6-methyl-quinolin-3-yl)meth-yl]quinazolin-4(3H)-one.
June 2010, Acta crystallographica. Section E, Structure reports online,
Copied contents to your clipboard!